E Mocci1, C Guillen-Ponce1, J Earl1, M Marquez2, J Solera3, M-T Salazar-López1, C Calcedo-Arnáiz1, E Vázquez-Sequeiros4, J Montans5, M Muñoz-Beltrán6, A Vicente-Bártulos6, C González-Gordaliza6, A Sanjuanbenito7, C Guerrero1, E Mendía7, E Lisa7, E Lobo7, J C Martínez2, F X Real8, N Malats2, A Carrato1. 1. Medical Oncology Department, Ramon y Cajal University Hospital, IRYCIS, Madrid, Spain. 2. Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. 3. Molecular Oncogenetics Unit, Institute of Medical and Molecular Genetics, La Paz Hospital, Madrid, Spain. 4. Digestive Department, Ramon y Cajal University Hospital, IRYCIS, Madrid, Spain. 5. Pathology Department, Ramon y Cajal University Hospital, IRYCIS, Madrid, Spain. 6. Radiology Department, Ramon y Cajal University Hospital, IRYCIS, Madrid, Spain. 7. Surgery Department, Ramon y Cajal University Hospital, IRYCIS, Madrid, Spain. 8. Epithelial Carcinogenesis Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain; Department de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain.
Abstract
PURPOSE: To describe the organisation of the registry and the preliminary results in terms of characteristics of high-risk pancreatic ductal adenocarcinoma (PDAC) families recruited to date and findings of the screening programme. To compare early onset sporadic cases (⩽50 years), sporadic cases (>50 years) and cases with family history of cancer, for PDAC possible risk factors. METHODS/PATIENTS: Families with hereditary cancer syndromes predisposing to PDAC were recruited from two main sources: Spanish hospitals participating in PanGenEU, a pan-European multicentre case-control study, and their genetic counseling unit. Individuals at high-risk of PDAC were enrolled into a screening programme, consisting of Endoscopic ultrasound, computerised tomography, magnetic resonance imaging. Genetic testing of candidate genes was offered according to each patient's risk. RESULTS: Among 577 consecutive PDAC cases, recruited via PanGenEU, 36 (6%) had ⩾2 first-degree relative with PDAC: Familial pancreatic cancer (FPC). So far PanGen-Fam has recruited 42 high-risk PDAC families; 25 (60%) had FPC. Five index cases with cancer were positive for BRCA2 and one for BRCA1 germline mutations. In the second year of prospective PDAC screening, one neuroendocrine tumour and a high-grade dysplasia lesion suspicious of carcinoma were diagnosed among 41 high-risk individuals. Furthermore EUS detected chronic-pancreatitis-like parenchymal changes in 15 patients. CONCLUDING STATEMENT: The identification and recruitment of PDAC high-risk families into the PanGen-Fam registry provides an opportunity to detect early onset cancer and precursor pancreatic cancer lesions at a potentially curative stage and to increase the knowledge of the natural history of the disease.
PURPOSE: To describe the organisation of the registry and the preliminary results in terms of characteristics of high-risk pancreatic ductal adenocarcinoma (PDAC) families recruited to date and findings of the screening programme. To compare early onset sporadic cases (⩽50 years), sporadic cases (>50 years) and cases with family history of cancer, for PDAC possible risk factors. METHODS/PATIENTS: Families with hereditary cancer syndromes predisposing to PDAC were recruited from two main sources: Spanish hospitals participating in PanGenEU, a pan-European multicentre case-control study, and their genetic counseling unit. Individuals at high-risk of PDAC were enrolled into a screening programme, consisting of Endoscopic ultrasound, computerised tomography, magnetic resonance imaging. Genetic testing of candidate genes was offered according to each patient's risk. RESULTS: Among 577 consecutive PDAC cases, recruited via PanGenEU, 36 (6%) had ⩾2 first-degree relative with PDAC: Familial pancreatic cancer (FPC). So far PanGen-Fam has recruited 42 high-risk PDAC families; 25 (60%) had FPC. Five index cases with cancer were positive for BRCA2 and one for BRCA1 germline mutations. In the second year of prospective PDAC screening, one neuroendocrine tumour and a high-grade dysplasia lesion suspicious of carcinoma were diagnosed among 41 high-risk individuals. Furthermore EUS detected chronic-pancreatitis-like parenchymal changes in 15 patients. CONCLUDING STATEMENT: The identification and recruitment of PDAC high-risk families into the PanGen-Fam registry provides an opportunity to detect early onset cancer and precursor pancreatic cancer lesions at a potentially curative stage and to increase the knowledge of the natural history of the disease.
Authors: Kasper A Overbeek; Djuna L Cahen; Marcia Irene Canto; Marco J Bruno Journal: Best Pract Res Clin Gastroenterol Date: 2016-11-05 Impact factor: 3.043
Authors: Louis de Mestier; Marie Muller; Jérôme Cros; Marie-Pierre Vullierme; Dewi Vernerey; Frédérique Maire; Safi Dokmak; Vinciane Rebours; Alain Sauvanet; Philippe Lévy; Pascal Hammel Journal: United European Gastroenterol J Date: 2019-01-12 Impact factor: 4.623
Authors: M Hidalgo; R Álvarez; J Gallego; C Guillén-Ponce; B Laquente; T Macarulla; A Muñoz; M Salgado; R Vera; J Adeva; I Alés; S Arévalo; J Blázquez; A Calsina; A Carmona; E de Madaria; R Díaz; L Díez; T Fernández; B G de Paredes; M E Gallardo; I González; O Hernando; P Jiménez; A López; C López; F López-Ríos; E Martín; J Martínez; A Martínez; J Montans; R Pazo; J C Plaza; I Peiró; J J Reina; A Sanjuanbenito; R Yaya; Alfredo Carrato Journal: Clin Transl Oncol Date: 2016-12-19 Impact factor: 3.405
Authors: Marcin R Lener; Aniruddh Kashyap; Wojciech Kluźniak; Cezary Cybulski; Agnieszka Soluch; Sandra Pietrzak; Tomasz Huzarski; Jacek Gronwald; Jan Lubiński Journal: Cancer Res Treat Date: 2016-07-28 Impact factor: 4.679
Authors: Iván Márquez-Rodas; Marina Pollán; María José Escudero; Amparo Ruiz; Miguel Martín; Ana Santaballa; Purificación Martínez Del Prado; Norberto Batista; Raquel Andrés; Antonio Antón; Antonio Llombart; Antonio Fernandez Aramburu; Encarnación Adrover; Sonia González; Miguel Angel Seguí; Lourdes Calvo; José Lizón; Álvaro Rodríguez Lescure; Teresa Ramón Y Cajal; Gemma Llort; Carlos Jara; Eva Carrasco; Sara López-Tarruella Journal: PLoS One Date: 2017-10-06 Impact factor: 3.240